Abeona Therapeutics Inc.

ABEO

US00289Y2063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
4.24 ^USD	+1.19%		-7.42%	-15.37%

18/06	Abeona Therapeutics Files for $300 Million Mixed Shelf, $75 Million At-The-Market Offering	MT
30/05	Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target	MT

Abeona Therapeutics Inc. Announces Appointment of Michael Amoroso as President and a Member of the Company's Board of Directors

May 19, 2021

Abeona Therapeutics Inc. announced Appointment of Michael Amoroso as President, Chief Executive Officer (CEO) and a member of the company's Board of Directors.

Latest news about Abeona Therapeutics Inc.

Abeona Therapeutics Files for $300 Million Mixed Shelf, $75 Million At-The-Market Offering	18/06	MT
Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target	30/05	MT
Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating	16/05	MT
Transcript : Abeona Therapeutics Inc., Q1 2024 Earnings Call, May 15, 2024	15/05
Abeona Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise	03/05	MT
Sector Update: Health Care Stocks Rise Late Afternoon	24/04	MT
Top Midday Decliners	23/04	MT
Transcript : Abeona Therapeutics Inc. - Special Call	23/04
Top Premarket Decliners	23/04	MT
Abeona Therapeutics Shares Slump After Plans to Reapply for Pz-cel Drug Approval	23/04	MT
Abeona Therapeutics Shares Down 53% After FDA Complete Response Letter	23/04	DJ
US FDA declines to approve Abeona's skin disorder treatment	23/04	RE
Abeona Therapeutics Inc. Provides Regulatory Update on Pz-Cel	23/04	CI
Sector Update: Health Care Stocks Edge Up Late Monday Afternoon	19/03	MT
Sector Update: Health Care Stocks Rise Monday Afternoon	18/03	MT
Sector Update: Health Care	18/03	MT
Abeona Therapeutics Shares Fall After 2023 Results, FDA Observations on Cleveland Facility	18/03	MT
Abeona Therapeutics Shares Drop 13% After FDA Inspection of Cleveland Facility	18/03	DJ
Transcript : Abeona Therapeutics Inc., 2023 Earnings Call, Mar 18, 2024	18/03
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03	CI
Abeona Says FDA Confirms Target Action Date For Pz-cel Application After Inspection	02/02	MT
Abeona Therapeutics Announces $50 Million Credit Facility	08/01	CI
Abeona Therapeutics Inc. announced that it expects to receive $50 million in funding	08/01	CI
Sector Update: Health Care Stocks Ease in Late Afternoon	28/11	MT

Chart Abeona Therapeutics Inc.

Duration

Period

More charts

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Companyâs lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Companyâs fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Companyâs development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Companyâs novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Abeona Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.24 USD

Average target price

16.7 USD

Spread / Average Target

+293.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ABEONA THERAPEUTICS INC.	-15.37%	17Cr
LONZA GROUP AG	+38.65%	3.94TCr
IQVIA HOLDINGS INC.	-8.62%	3.85TCr
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	3.07TCr
ICON PUBLIC LIMITED COMPANY	+10.74%	2.59TCr
CELLTRION, INC.	-13.50%	2.6TCr
UNITED THERAPEUTICS CORPORATION	+44.87%	1.41TCr
MEDPACE HOLDINGS, INC.	+34.36%	1.27TCr
BIO-TECHNE CORPORATION	-7.14%	1.13TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	1.06TCr

Other Biotechnology & Medical Research